<DOC>
	<DOCNO>NCT01392768</DOCNO>
	<brief_summary>The purpose study determine whether levetiracetam adjunctive therapy effective treatment partial seizure , without secondary generalization , associate refractory focal epilepsy .</brief_summary>
	<brief_title>Efficacy Safety Levetiracetam Partial Seizures Control , With Without Secondary Generalization</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>Patients sex , age 04 65 year , remain feasibility legal guardian accordance need , able understand provide write informed consent able allow compliance treatment requirement protocol ; Patient´s weight ≥ 20kg ; Consistent diagnosis refractory focal epilepsy , without secondary generalization ; Patient onset seizure least 02 year precede screen visit ; Presence least 12 partial seizure 03 month precede screen visit ( 04 seizure per month ) ; Only seizures generate motor manifestation record study . Absence brain injury progressive expansive , previously document CT scan , MRI image test applicable ( last 05 year ; Patient electroencephalogram perform 02 year visit ; Subject stable regimen ( minimum 01 month ) one three antiepileptic drug . Vagus nerve stimulation 04 week prior V1 , use benzodiazepine 07 consecutive day consider concomitant epileptic drug ) Patients : Seizures non epileptic origin ; Pseudoseizures ; Seizures occur cluster pattern ( 03 seizure 30 minute ) , 03 month precede screen visit ( V1 ) ; History status epilepticus take antiepileptic drug 03 month precede screen visit ( V1 ) . Epileptic syndrome occurs cognitive deficit secondary epilepsy evolve brain disease ; History schizophrenia suicide attempt ; Patients psychiatric ill ongoing ; Presence severe mental retardation etiology ; Previous exposure levetiracetam ; Women childbearing age test positive pregnancy , use acceptable contraceptive method , agree practice reliable contraception study ; Woman pregnancy lactation period ; Diagnosis renal hepatic failure ; Patients genetic syndrome ; Patient take prohibited medication ( Item 9.3 ) ; Participation last one year clinical protocol , unless direct benefit subject ; Relatives sponsor´s study site´s employee ; Current evidence clinically significant disease : hematopoietic , gastrointestinal , cardiovascular , hepatic , renal , neurological , endocrine , psychiatric , autoimmune , pulmonary , another disease block subject participation ; Any find clinical observation ( anamnesis physical exam ) laboratory abnormality ( e.g. , blood glucose , blood count ) , disease ( example , liver , cardiovascular system , lung ) therapy , opinion investigator , may endanger subject interfere endpoint study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Partial</keyword>
	<keyword>Seizures</keyword>
	<keyword>Adjunctive</keyword>
</DOC>